The headline numbers describe different things
China's most-quoted inbound figure is 1.28 million international patient visits in 2025, up 73.6%, attributed to a National Health Commission report. We could not retrieve that report, and no outlet citing it links to the commission's own site.
The most-quoted medical tourism figure from China's flagship medical-tourism zone — 860,000 visits to Boao Lecheng in 2025 — counts mostly domestic patients getting treated at home rather than abroad. The zone's own overseas-patient figure for the same year was about 9,300.
And an estimate from within the industry put patients who actually travelled to China for care at under 10,000 in 2025 — roughly one fortieth of the attributed national total.
We do not publish a market-size estimate of our own; we have no defensible way to produce one. What follows is every published figure we could find, what each one counts, and where they disagree — so that anyone citing a China medical-tourism number can see which number they are citing.
Three kinds of evidence appear below and they are not interchangeable: figures a government body publishes and we can retrieve, figures widely attributed to a named body that we could not retrieve, and estimates made by named people in the industry. Each card says which it is. The "what it counts" line matters more than the number.
1.28 million China (national)
International patient visits at foreign-related hospitals
What it counts: Visits by international patients at hospitals designated for foreign-related care. A visit, not a patient, and not limited to people who travelled to China for treatment.
Reported as up 73.6% against three years earlier · Year: 2025
Attributed Attributed to the National Health Commission, 2025 report on foreign-related medical services, 2026-02-28
Repeated by Chinese media with the same report title. We could not retrieve the report, and no outlet citing it links to an nhc.gov.cn page.
413,000 China (national)
Of the above, visits made "purely for medical treatment"
What it counts: The subset of the 1.28 million that the same report describes as treatment-driven rather than incidental to travel or work.
Year: 2025
Attributed Same attributed National Health Commission report, as reported by 36Kr, 2026-04-23
Same caveat as above: the underlying report is not retrievable.
over ¥80 billion China (national)
Medical revenue at key inbound hospitals
What it counts: Revenue booked by the hospitals the report classifies as key inbound providers. Revenue, not spend by foreign patients alone — domestic patients at the same hospitals are included.
Reported as up 73.6% against three years earlier · Year: 2025 (first three quarters)
Attributed Same attributed National Health Commission report, as reported by 36Kr, 2026-04-23
We have not reproduced this figure as a market size: it is hospital revenue, and the report does not publish how much of it came from international patients.
possibly under 10,000 China (national)
Inbound foreign patients who travelled to China for treatment
What it counts: An industry executive's estimate of patients who actually travelled to China for care — the closest thing we found to the number the attributed 413,000 is usually read as.
Year: 2025
Estimate Cai Qiang, Shengnuo Yijia (a Chinese medical-travel agency), quoted in Chinese media, 2026-02-28
This is an estimate by a named industry figure, not a statistic. We include it because it is roughly one fortieth of the attributed national figure, and a reader cannot judge either number without knowing that.
73,200 Shanghai
Foreign-passport patient visits at public hospitals
What it counts: Visits by holders of a foreign passport at public hospitals only. Excludes private and international-pilot clinics, and counts visits rather than individuals.
Up over 8% on 67,600 in 2024 · Year: 2025
Official Shanghai Municipal Health Commission, published by the Shanghai Municipal Government, 2026-02-27
The most precisely defined figure we found anywhere. It is also the narrowest: foreign passports, public hospitals, one city.
413,700 Boao Lecheng pilot zone, Hainan
Medical-tourism visits to the zone
What it counts: All medical-tourism visits to the zone — and the zone's model is largely "get treatment at home rather than abroad", so this counts predominantly DOMESTIC Chinese patients, not inbound travellers.
Up 36.8% year on year · Year: 2024
Official Hainan Provincial People's Government, 2025-06-30
Frequently quoted as evidence of inbound demand. Read the "counts" column before doing that: this is a zone-visit count, not an inbound-patient count.
over 9,300 Boao Lecheng pilot zone, Hainan
Overseas patients treated in the zone
What it counts: Patients from 14 countries and regions — the actual inbound component of the zone, against the ~860,000 total visits reported for the same year.
Reported as a sixfold rise on the previous quarter · Year: 2025
Attributed Fu Sheng, administrator of the Lecheng zone, quoted by China News Service, 2026-01-27
If you want one number for real inbound patients at China's flagship medical-tourism zone, this is it — and it is about one per cent of the total visit count.
540+ Boao Lecheng pilot zone, Hainan
Unapproved-elsewhere drugs and devices introduced to the zone
What it counts: Medicines and devices licensed for use in the zone before mainland approval — the zone's core policy advantage, and the reason a patient might choose it.
More than 100 added during 2025 alone · Year: to January 2026
Attributed Reported by China News Service from the Lecheng administration, 2026-01-27
Both of these are put forward as the number of patients who came to China for treatment in 2025. Neither is a statistic we produced; both are reported. Read together they are the clearest evidence that this market is not yet measured in a way anyone can compare.
413,000
patients treated, attributed to the national report
≈ 40×
under 10,000
patients who travelled to China for care, industry estimate
Cite this page
APA: China Hospitals Guide. (2026). China medical tourism statistics 2026: what the published data shows. https://chinahospitalsguide.com/china-medical-tourism-statistics/
MLA: "China Medical Tourism Statistics 2026: What the Published Data Shows." China Hospitals Guide, 2026, chinahospitalsguide.com/china-medical-tourism-statistics/. Accessed [date].
If you are citing a specific figure: please cite the original source named on its card, not this page. We are a map of the published data, not its author.
What the published record does not contain
These are the gaps we hit while assembling the cards above. They are as much a finding as the figures are — the absence is why the numbers do not reconcile.
No comparable national series
China publishes no single official inbound-medical-tourism series. The figures above are produced by different bodies, for different years, under different definitions, and are not additive.
No national breakdown by source country
Country-level detail exists only provincially and anecdotally — Mongolia at Inner Mongolia hospitals, Russia at Heilongjiang border hospitals, Central Asia and the Middle East at Lecheng. No national table is published.
No national breakdown by treatment
Reported categories are Traditional Chinese Medicine, cardiac care, oncology and rehabilitation, but no shares are published, so no treatment can be ranked by inbound volume.
No current outbound figures either
For Chinese patients travelling abroad, the only figures we could retrieve are dated or company-sourced. Note that most English-language "China medical tourism" reporting is about this outbound flow, not about patients coming to China.
What treatment costs in China
Reference ranges for international self-pay patients, taken from the condition guides we publish. Every row links to the guide it came from, so you can check the range in its full clinical context. These are starting points, not quotes.
| Procedure | China range (USD) | Notes |
|---|
| Coronary Artery Bypass Grafting (CABG) | $18,000–$45,000 | |
| Heart valve replacement | $10,000–$15,000 | |
| Lobectomy (lung cancer surgery) | $15,000–$30,000 | |
| Breast surgery (mastectomy or lumpectomy) | $8,000–$15,000 | |
| Liver cancer surgery (resection) | $20,000–$40,000 | |
| Gastrectomy (surgery only) | $14,000–$25,000 | |
| Colorectal cancer surgery | $12,000–$20,000 | |
| Craniotomy (open brain surgery) | $15,000–$35,000 | |
| Knee replacement | $8,000–$12,000 | per knee |
| Hip replacement | $8,000–$12,000 | |
| Spinal fusion (1–2 levels) | $12,000–$18,000 | |
| Total bilateral DBS (evaluation, device, surgery, stay, programming) | $40,000–$80,000 | |
| Epilepsy resection surgery (e.g. temporal lobectomy) | $8,000–$20,000 | |
| IVF cycle | $3,000–$8,000 | |
| LASIK (per eye) | $1,100–$1,800 | both eyes typically $2,200–$3,600 |
| Cataract surgery | $800–$1,500 | per eye; premium IOLs more |
| Dental implant | $620–$1,700 | |
| Approved CD19 or BCMA CAR-T | $89,000–$170,000 | drug plus the full treatment course; quoted per case |
| Radical hysterectomy (early stage) | $6,000–$12,000 | |
| Mechanical thrombectomy (acute) | $10,000–$20,000 | within the treatment window |
Indicative 2026 ranges for international self-pay patients; professional fees, travel, accommodation and complications are not included. See all procedure prices or the condition guides for the full breakdown behind any row.
China vs Singapore, on published benchmarks
The prices above are ours. This table puts ours next to a government's own bill statistics: Singapore's Ministry of Health publishes the median total bill actually charged for each surgical procedure, which is the closest thing in the region to a published self-pay benchmark. Two procedures survive the comparison — and the two that do not are explained underneath, because the reason they fail is the same reason the market figures on this page disagree.
| Procedure | China our published range | Singapore median total bill, private hospitals |
|---|
| Coronary artery bypass graft (CABG) | $18,000–$45,000 | S$112,977S$100,656–S$122,421 · MOH code SD742H · source |
| Total knee replacement (unilateral) | $8,000–$12,000 | S$43,138S$36,895–S$48,590 · MOH code SB810K · source |
Singapore figures are median total hospital bills published by MOH, in Singapore dollars — the currency MOH publishes them in. They are inclusive of GST and shown before insurance payouts. We do not convert them.
Why there is no US column
There is no US column because the United States publishes no national self-pay price benchmark for these procedures. The figures usually quoted are commercial-insurance allowed amounts or Medicare payments — not the price a self-paying international patient is billed. Comparing a Chinese self-pay bill with an American insurance payment would not be a comparison.
Why the other procedures are missing
- Hip replacement. The MOH code for a primary total hip replacement with augmentation (SB723H) covers extra implants or bone grafts, so its S$57,900 median describes a more complex case than a routine hip. We would rather omit the row than overstate it.
- Heart valve replacement. MOH publishes bill figures for valve surgery only by public ward class. Those are subsidised prices for Singapore Citizens and say nothing about what an international self-pay patient is charged.
Where the China figures come from
Each is the range published in the linked condition guide, which also documents what the price includes. See the country pages for US patients and Singapore patients.
Our own data
We are a directory of 58 hospitals across 13 cities, and the ranges above come from that work. Composition of the directory — which cities, which specialties, how it was assembled and what we deliberately leave out — is documented separately so it is not confused with market data.
Directory composition, row-level methodology and the full row-level dataset live in the Hospital Access Report 2026. Nothing on that page is a measurement of the market.
Methodology and sources
How figures get onto this page
Every card names the body that published the figure and links to where we read it. We add a figure only if we can point a reader at a source for it. Where we could not retrieve the underlying report we say so on the card and label the figure "attributed" rather than confirmed — a figure repeated by twenty outlets is still one attribution, not twenty confirmations.
What we deliberately leave out
We publish no market-size estimate of our own, because we have no defensible method for producing one. We publish no accreditation claims: a hospital's JCI status can only be stated after row-by-row verification against the accreditor's own register. We publish no clinical outcomes or surgeon-level data, because we have no defensible source for them in China.
Price ranges
China figures are the ranges published in our own condition and procedure guides, and every row links to its guide. The Singapore figures in the benchmark table are medians of actual transacted bills published by Singapore's Ministry of Health, shown in the currency MOH publishes them in and linked row by row. We do not convert currencies. We publish no US column, because no comparable published self-pay benchmark exists for the United States.
Corrections
If a figure is wrong, or a source has moved, or you know of a published figure we have missed, write to contact@chinahospitalsguide.com. We would rather publish a correction than carry a stale claim.
Download the datasets
Both are free to use with attribution. The statistics file carries a source column and a "what it counts" column for every figure, so the numbers stay checkable once they leave this page.
Statistics CSV Hospital directory CSV Hospital JSONNeed a hospital match for a specific case?
Send your records for a free case review — we will tell you which hospitals are actually relevant to your condition, and what a written quote is likely to look like.
Start a free case review🛡️
100% Independent GuidanceWe are not affiliated with any hospital. We don't take commissions. Our only goal is finding the right care for you.